SILO PHARMA, INC. Interest Expense Nonoperating
SILO PHARMA, INC. (SILO) reported Interest Expense Nonoperating of $2.87 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-13
- SILO PHARMA, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $2.87K, a 73.85% increase year-over-year.
- SILO PHARMA, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $3.37K, a 63.26% increase year-over-year.
- SILO PHARMA, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $32.70K, a 11835.04% increase year-over-year.
- SILO PHARMA, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $886.00, a 18.04% decline year-over-year.
- SILO PHARMA, INC. interest expense nonoperating for fiscal 2023 was $4.87K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.87K 10-Q · filed 2026-08-13 | $6.24K 10-Q · filed 2026-08-13 | $38.94K derived: sum of 3 quarters · filed 2026-08-13 | $39.83K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $3.37K 10-Q · filed 2026-05-14 | $36.08K derived: sum of 2 quarters · filed 2026-05-14 | $36.96K derived: sum of 3 quarters · filed 2026-05-14 | $38.61K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $32.70K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $33.59K derived: sum of 2 quarters · filed 2026-04-14 | $35.24K derived: sum of 3 quarters · filed 2026-08-13 | $37.30K POS AM · filed 2026-04-14 |
| 2025-09-30 | $886.00 10-Q · filed 2025-11-13 | $2.53K derived: sum of 2 quarters · filed 2026-08-13 | $4.60K 10-Q · filed 2025-11-13 | $4.87K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.65K 10-Q · filed 2026-08-13 | $3.71K 10-Q · filed 2026-08-13 | $3.99K derived: sum of 3 quarters · filed 2026-08-13 | $5.07K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.07K 10-Q · filed 2026-05-14 | $2.34K derived: sum of 2 quarters · filed 2026-05-14 | $3.42K derived: sum of 3 quarters · filed 2026-05-14 | $5.28K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $274.00 derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $1.35K derived: sum of 2 quarters · filed 2026-04-14 | $3.21K derived: sum of 3 quarters · filed 2026-04-14 | $5.08K POS AM · filed 2026-04-14 |
| 2024-09-30 | $1.08K 10-Q · filed 2025-11-13 | $2.94K derived: sum of 2 quarters · filed 2025-11-13 | $4.81K 10-Q · filed 2025-11-13 | $5.08K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.86K 10-Q · filed 2025-08-13 | $3.73K 10-Q · filed 2025-08-13 | $4.00K derived: sum of 3 quarters · filed 2025-08-13 | $5.08K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.87K 10-Q · filed 2025-05-09 | $2.14K derived: sum of 2 quarters · filed 2025-05-09 | $3.22K derived: sum of 3 quarters · filed 2025-05-09 | $5.08K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $273.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $1.35K derived: sum of 2 quarters · filed 2025-03-28 | $3.21K derived: sum of 3 quarters · filed 2025-03-28 | $4.87K 10-K · filed 2025-03-28 |
| 2023-09-30 | $1.08K 10-Q · filed 2024-11-12 | $2.94K derived: sum of 2 quarters · filed 2024-11-12 | $4.60K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $1.86K 10-Q · filed 2024-08-13 | $3.52K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |